NDLI: Reprint of: The prostate cancer genome: Perspectives and potential.

Please wait, while we are loading the content...

The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies.

Genetic predisposition to prostate cancer: Update and future perspectives.

Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.

The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer.

The effect of length of ureteral resection on benign ureterointestinal stricture rate in ileal conduit or ileal neobladder urinary diversion following radical cystectomy.

Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma.

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.

Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.

Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms.

Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer.

Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.

Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer.

The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma.

Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience.

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis.

Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section.

Improved perioperative outcome with norepinephrine and a restrictive fluid administration during open radical cystectomy and urinary diversion.

Snail predicts recurrence and survival of patients with localized clear cell renal cell carcinoma after surgical resection.

The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma.

Commentary on 'Asymptomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of prostate-specific antigen.' Agnihotri S, Mittal RD, Kapoor R, Mandhani A, Department of Urology & Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.: Urol Oncol 2014; [Epub ahead of print]. doi: 10.1016/j.urolonc.2014.03.004.

Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population.

Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy.

Clinical significance of tumor-derived IL-1ß and IL-18 in localized renal cell carcinoma: Associations with recurrence and survival.

African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model.

Toward a prostate cancer precision medicine.

Reprint of: The prostate cancer genome: Perspectives and potential.

Year: 2015 Volume: 33 Issue: 1

Year: 2014 Volume: 32

Year: 2013 Volume: 31

Year: 2012 Volume: 30

Year: 2011 Volume: 29

Year: 2010 Volume: 28

Year: 2009 Volume: 27

Year: 2008 Volume: 26

Year: 2007 Volume: 25

Year: 2006 Volume: 24

Year: 2005 Volume: 23

Reprint of: The prostate cancer genome: Perspectives and potential.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Barbieri, Christopher E. Tomlins, Scott A.
Description	Author Affiliation: Barbieri CE ( Department of Urology, Weill Medical College of Cornell University, New York, NY); Tomlins SA ( Department of Pathology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI)
Abstract	OBJECTIVES: Prostate cancer has a variable clinical course, and molecular characterization has revealed striking mutational heterogeneity that may underlie the unpredictable clinical behavior of the disease. Advances in technology have resulted in a rapid expansion of our understanding of the genomic events responsible for the development and progression of prostate cancer. In this review, we discuss the genomic alterations underlying prostate cancer, and potential to utilize this knowledge for diagnostic and prognostic benefit. METHODS AND MATERIALS: We reviewed the relevant literature, with a focus on recent studies on somatic alterations in prostate cancer. RESULTS: Pathways known to affect tumorigenesis across a wide spectrum of tissues are dysregulated, such as the PI3K pathway, cell cycle control, and chromatin regulation. Lesions more specific to prostate cancer include alterations in androgen signaling, gene fusions of ETS transcription factors, and mutations in SPOP. Accumulating data suggests that prostate cancer can be subdivided based on a molecular profile of these genetic alterations. CONCLUSIONS: These findings raise the possibility that prostate cancer could transition from a poorly understood, heterogeneous disease with a variable clinical course to a collection of homogenous subtypes, identifiable by molecular criteria, associated with distinct risk profiles, and perhaps amenable to specific management strategies or targeted therapies.
File Format	HTM / HTML
ISSN	10781439
Issue Number	2
Volume Number	33
e-ISSN	18732496
Journal	Urologic Oncology: Seminars and Original Investigations
Language	English
Publisher	Elsevier
Publisher Date	2015-02-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Urology Discipline Oncology Genomics Methods Prostatic Neoplasms Genetics Genetic Predisposition To Disease Humans Male Prognosis Pathology Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Urology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The prostate cancer genome: perspectives and potential.

Genetic predisposition to prostate cancer: Update and future perspectives.

Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.

High-risk prostate cancer: a disease of genomic instability.

The genetic epidemiology of prostate cancer and its clinical implications.

Radical prostatectomy: positive surgical margins matter.

Prostate cancer risk-associated genetic markers and their potential clinical utility.

Genetic analysis of the principal genes related to prostate cancer: a review.

Reprint of: The prostate cancer genome: Perspectives and potential.

Similar Documents

The prostate cancer genome: perspectives and potential.

Genetic predisposition to prostate cancer: Update and future perspectives.

Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.

High-risk prostate cancer: a disease of genomic instability.

The genetic epidemiology of prostate cancer and its clinical implications.

Radical prostatectomy: positive surgical margins matter.

Prostate cancer risk-associated genetic markers and their potential clinical utility.

Genetic analysis of the principal genes related to prostate cancer: a review.

Reprint of: The prostate cancer genome: Perspectives and potential.